A Case of Paranoid Schizophrenia Treated with Individualised Homoeopathy

Abstract

Background Schizophrenia is a chronic, complex, highly disabling, serious mental disorder characterised by distortions of thinking and perception. Psychotropic medicines used for management are effective but are characterised by severe limitations. Alternate safe and effective treatment regimens are being explored. Homoeopathy is a system of medicine based on individualistic approach with potential relevance to psychiatry.

Purpose The purpose of this case report is to demonstrate the utility of homoeopathy in management of schizophrenia.

Client Description A 37-year-old female patient was brought by her husband to outpatient department of psychiatry. Auditory hallucinations, referential delusions, thought withdrawal and emotional outbursts were reported during the interview.

Measures and Outcome The physician's initial assessment lead to diagnosis of schizophrenia and confirmed as paranoid schizophrenia by the psychiatrist. Clinical Global Impression-Schizophrenia (CGI-SCH) was used to assess the severity of symptoms at baseline and consecutive follow-ups for 18 months.

Intervention The patient was prescribed a single dose of Natrum carbonicum 200C and repeated only once after 8 months, when sleep disturbance demanded repetition.

Results Baseline CGI-SCH scores in domains of severity of illness and degree of change were 29 and 20, respectively, which reduced to 5 (normal) in both domains by 4 months and remained the same for the next 2 years.

Implications This case study reinforces the utility of homoeopathy in schizophrenia and throws light on importance of a thorough case taking of psychiatric patients to elicit totality of symptoms to arrive at the similimum.

Keywords

schizophrenia - homoeopathy - totality of symptoms - Natrum carbonicum - CGI-SCH

Criteria for Inclusion in the Authors'/Contributors' List

1. Dr Deepthi Gilla was involved in idea conception, prescription, compilation, acquisition of data, analysis and interpretation of data, manuscript preparation and final approval of the version to be published.

2. Dr Mohan N.D. was involved in confirmation of diagnosis, ruling out co-morbidities, guidance regarding withdrawal of antipsychotic medication. manuscript review, overall guidance and final approval of the version to be published.

3. Dr Sreelakshmy S.R. was involved in drafting, documentation, proof reading and final approval of the version to be published.

Publication History

Article published online:
29 December 2022

• References

• 1 Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P&T 2014; 39 (09) 638-645
• 2 Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335 (7610): 91-95
• 3 Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 388 (10039): 86-97
• 4 Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules 2018; 23 (08) 2087 DOI: 10.3390/molecules23082087.
• 5 Murray R, Lopez A. Global Burden Disease: A Comprehensive Assessment of Mortality and Disability from Injuries and Risk Factors in 1990 and Projected to 2020. Cambridge: Harvard University Press; 1996
• 6 Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10 (01) 425-448
• 7 De Luca V, Tharmalingam S, Müller DJ, Wong G, de Bartolomeis A, Kennedy JL. Gene-gene interaction between MAOA and COMT in suicidal behavior: analysis in schizophrenia. Brain Res 2006; 1097 (01) 26-30
• 8 Haller CS, Padmanabhan JL, Lizano P, Torous J, Keshavan M. Recent advances in understanding schizophrenia. F1000Prime Rep 2014; 6: 57 DOI: 10.12703/p6-57.
• 9 Munetz M. Clinical Handbook of Schizophrenia edited by Kim T. Mueser and Dilip V. Jeste; New York, Guilford Press, 2008, 650 pages, $75. Psychiatric Services 2008; 59 (11) 1352-1352 DOI: 10.1176/ps.2008.59.11.1352.
• 10 Kirkpatrick B, Miller B, García-Rizo C, Fernandez-Egea E. Schizophrenia: a systemic disorder. Clin Schizophr Relat Psychoses 2014; 8 (02) 73-79
• 11 World Health Organisation. The ICD Classification of Mental and Behavioural Disorders. 10th edition.. Delhi: A.I.T.B.S.Publishers $ Distributors; 2007
• 12 Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th edition)2014 102 Diagnostic and Statistical Manual of Mental Disorders: DSM-5 (5th edition). Washington, DC: American Psychiatric Association; 2013
• 13 Haro JM, Kamath SA, Ochoa S. et al; SOHO Study Group. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl 2003; 107 (416, s416) 16-23
• 14 Kane JM, Correll CU. Past and present progress in the pharmacologic treatment of schizophrenia. J Clin Psychiatry 2010; 71 (09) 1115-1124
• 15 Lewith GT, Breen A, Filshie J. et al. Complementary medicine: evidence base, competence to practice and regulation. Clin Med (Lond) 2003; 3 (03) 235-240
• 16 Jayakumar M, Lalitha KS. A clinical study on paranoid schizophrenia and its homoeopathic management. IOSR journal of dental and medical sciences May 2019; 18 (05) 52-56
• 17 Bell IR, Koithan M, Brooks AJ. Testing the nanoparticle-allostatic cross-adaptation-sensitization model for homeopathic remedy effects. Homeopathy 2013; 102 (01) 66-81
• 18 Oberai P, Gopinadhan S, Sharma A, Nayak C, Gautam K. Homoeopathic management of schizophrenia: a prospective, non-comparative, open-label observational study. Ind J Res Hom 2016; 10 (02) 108 DOI: 10.4103/0974-7168.183877.
• 19 Novick D, Haro JM, Suarez D, Vieta E, Naber D. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009; 108 (1-3): 223-230
• 20 Campos MS, Garcia-Jalon E, Gilleen JK, David AS, Peralta VM, Cuesta MJ. Premorbid personality and insight in first-episode psychosis. Schizophr Bull 2011; 37 (01) 52-60
• 21 Chaiyakunapruk N, Chong H, Teoh S, Wu D, Kotirum S, Chiou C. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat 2016; 357 DOI: 10.2147/ndt.s96649.
• 22 Marutani T, Chhim S, Nishio A, Nosaki A, Fuse-Nagase Y. Quality of life and its social determinants for patients with schizophrenia and family caregivers in Cambodia. PLoS One 2020; 15 (03) e0229643 DOI: 10.1371/journal.pone.022964.